- Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
-
Kang JH, Ryoo NY, Shin DW, Trojanowski JQ, Shaw LM
- KMID: 2285545
- Korean J Physiol Pharmacol.
- 2014 Dec;18(6):447-456.
- doi: 10.4196/kjpp.2014.18.6.447
Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled... -
- CITED
-
- Close
- SHARE
-
- Close
